On January 19th, the New York Times and the PBS news program “Frontline” are each scheduled to run stories exposing lax regulations in the U.S. and Canada around dietary supplement clinical science, health claims and manufacturing processes – including omega-3 products – and how these regulatory gaps place patients at risk. These stories come on the heels of actions by the U.S. Department of Justice (DOJ), which in November announced actions against dietary supplement makers and marketers, in collaboration with the U.S. Food and Drug Administration (FDA), the Department of Defense (DOD), the Federal Trade Commission (FTC), the U.S. Postal Service (USPS), and the U.S. Anti-Doping Agency (USADA)
In addition the FDA in December resolved to more closely regulate the dietary industry by creating the Office of Dietary Supplement Programs. All of which serve to raise serious concerns over the safety of taking a dietary supplement.
